In the extremely competitive world of Big Pharma, companies have to be
careful to keep all of their ducks in neat little rows. I have made no
secret of the fact that I believe Lilly (NYSE: LLY )
struggles in that regard, and yesterday's surprising announcement that
the FDA rejected empagliflozin over manufacturing issues at a plant
owned and operated by its partner Boehringer Ingelheim doesn't help matters.
Continue here to the full article:
What Does This Rejection Mean for Eli Lilly?
No comments:
Post a Comment